THU0536 efficacy and post-vaccination antibody titer data in children with caps aged 28 days to 4 years treated with canakinumab
Y Uziel, P Brogan, M Hofer, J Kuemmerle-Deschner… - 2015 - ard.bmj.com
Background Canakinumab (CAN) has proven efficacy in patients with CAPS aged≥ 2 years
1. However, patients can require treatment in infancy where CAN has not yet been studied …
1. However, patients can require treatment in infancy where CAN has not yet been studied …
THU0536 Efficacy and Post-Vaccination Antibody Titer Data in Children with Caps Aged 28 Days to 4 Years Treated with Canakinumab
Y Uziel, P Brogan, M Hofer… - Annals of the …, 2015 - search.proquest.com
Background Canakinumab (CAN) has proven efficacy in patients with CAPS aged≥ 2 years
1. However, patients can require treatment in infancy where CAN has not yet been studied …
1. However, patients can require treatment in infancy where CAN has not yet been studied …